secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001601830-25-000040
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board
--------------------------------------------------------------------------------

- Elaine Sun and Dr. Namandjé Bumpus appointed to Board effective March 15, 2025, expanding board from 8 to 10.
- Dr. Bumpus served as FDA Principal Deputy Commissioner until Dec 2024, brings regulatory and AI-in-science expertise.
- Elaine Sun is COO/CFO of Mammoth Biosciences, ex-CFO of Halozyme, with 30 years life sciences finance experience.
- New committees: R&D and Technology; Sun chairs Audit, Bumpus joins Nominating, R&D, and Technology committees.
- Director compensation policy amended to cover new committee roles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/rxrx-20250315.htm
  HTML page:      https://secwatch.observer/filing/0001601830-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer